Delisting risk
ESLA · NASDAQ · Biotechnology

Estrella Immunopharma (ESLA)

Develops ARTEMIS T-cell therapies for B-cell malignancies.

$0.6900
At close−0.00 (−0.22%)

Something off on this page? Send us feedback.

Next report
Dec 2, 2026
estimated · in 90 days
EPS estimate
−$0.08
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
Reported−$0.03−$0.06−$0.15−$0.13−$0.02−$0.05−$0.05Pending
Estimate−$0.12−$0.11−$0.07−$0.19−$0.18−$0.08−$0.09−$0.08
Surprise+76.1%+45.5%−114.3%+30.3%+91.0%+40.5%+44.4%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Dec '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Dec 2026−$0.08
Aug 2026−$0.09−$0.05+44.4%
May 2026−$0.08−$0.05+40.5%
Mar 2026−$0.18−$0.02+91.0%
Nov 2025−$0.19−$0.13+30.3%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Sep 2024
May 2024
Feb 2024
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2, 2026−$0.08
Aug 13, 2026−$0.09−$0.05+44.4%−0.2%
May 15, 2026−$0.08−$0.05+40.5%+0.9%
Mar 18, 2026−$0.18−$0.02+91.0%+1.9%
Nov 12, 2025−$0.19−$0.13+30.3%+4.8%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 11, 2025
May 14, 2025
Feb 15, 2025
Nov 14, 2024
Sep 27, 2024
May 14, 2024
Feb 14, 2024
Sep 30, 2023
Jun 29, 2023
Mar 30, 2023
Dec 31, 2022
Sep 29, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 29, 2021
Jun 30, 2021